Carolina Infusion, Ridgeland, SC

Is Carolina Infusion registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Carolina Infusion hold a South Carolina pharmacy license?

State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054020797 for CAROLINA INFUSION LLC, RIDGELAND, SC, status NOT RENEWED, as of Nov 13, 2026.

Has Carolina Infusion had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (May 22, 2023) for Carolina Infusion. State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Carolina Infusion
Location
Ridgeland, SC
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
3
Warning letters on FDA’s actions page
1
Latest action on that page
Aug 18, 2026
FDA Data Dashboard inspections
0 inspections; 0 published Form 483s
Form 483 text on this page
1 Form 483, 6 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Carolina Infusion, a 503A facility, with 4 dated actions.

Document
Aug 18, 2026Form 483483 Issued 08/18/2026fda.gov
Jan 24, 2025Form 483483 Issued 01/24/2025FDA copy (archived)
May 22, 2023Warning letterWarning Letter (05/22/2023)FDA copy (archived)
Aug 12, 2022Form 483483 Issued 08/12/2022FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Carolina Infusion, LLC, Ridgeland, SC (FEI number 3015826782), matched to this page by exact name, city and state. It lists no classified inspection under this name at that site. Dashboard firm profile.

Form 483s FDA has published for this site

No published Form 483 for FEI 3015826782 was found in the dashboard’s list of published 483s on Nov 15, 2026. FDA publishes only some 483s, so this does not mean none was issued.

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 6 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jan 14, 2025 to Jan 24, 2025: 6 observations

Firm on the cover
Carolina Infusion, 95 Bees Creek Rd, Ridgeland, SC 29936-7540
FEI number
3015826782
Establishment type on the cover
Producer o f Sterile and Non-Sterile Drug Products
FDA district office on the cover
1201 Main Street, Suite 7200 Dallas, TX 75202
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Materials were exposed to lower than ISO 5 quality air.

Specifically,

A. The <Redacted B4> swabs used to collect samples of compounded drug products intended for sterility testing were observed to have been opened and placed in the ISO 7 area. For example:

• On 1/15/2025, during the compounding of TRI-MIX 30/2/40 Injectable, Lot# 01152025@ <Redacted B4> BUD 2/10/2025, it was observed that the operator filtered a drop of the solution intended to be sterile onto a swab that had been opened and exposed to the ISO 7 hallway while being carried to the ISO 5 Biological Safety Cabinet (BSC), Equipment ID 49302 located in Compounding Room <Redacted B4>

• On 1/15/2025, during the compounding of TEST CYP/DHEA (SESAME) 200 mg/2.5 mg/ml, Injectable Lot# 011 52025@ <Redacted B4> BUD 2/14/2025, it was observed that the operator opened a new bag of swabs to collect samples; however, during the cleaning of the ISO 5 Laminar Airflow Hood (LAFH), the opened bag of swabs was placed on a cart in the ISO 7 Compounding Room <Redacted B4> and would be used to perform testing inside the ISO 5 hood for the next batch of drug product intended to be sterile. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 2

Inadequate routine environmental monitoring in the ISO 5 area.

Specifically,

Environmental monitoring (EM) of the ISO 5 LAFH and BSC is inadequate. Air sampling for environmental monitoring in each ISO 7 compounding room is conducted[ <Redacted B4> by a third-party company; however, active air monitoring and the use of settle plates have never been conducted in these ISO 5 areas. There are <Redacted B4> ISO 5 LAFHs in Compounding Room <Redacted B4> and <Redacted B4> ISO 5 BSCs in Compounding Room <Redacted B4>

Observation 3

Failure to conduct media fills that closely simulate aseptic production operations under the worst-case, most-challenging, and stressful conditions.

Specifically,

The media fill process does not fully simulate the production of sterile compounded drugs. Your firm conducted a media fill every <Redacted B4> using purchased kit to aseptically transfer a non-sterile solution from <Redacted B4> control vials to <Redacted B4> through <Redacted B4>. While this media fill process simulates the production of vial products, it does not account for the production of pre-filled syringes. For <Redacted B4> example, your firm produced <Redacted B4> pre-filled syringes of Semaglutide/Cyanocobalamin 9/2 mg/mL injection (Lot# 012122025@ <Redacted B4> dated 1/21/2025, with a BUD of 2/20/2025); however, the media fill process does not simulate the production of sterile pre-filled syringes.

Observation 4

Smoke studies were inadequately performed under dynamic conditions.

Specifically,

Your firm has no documented evidence demonstrating that the smoke study in the ISO 5 LAFHs or BSCs was conducted under dynamic conditions. The smoke study is performed <Redacted B4> by a third-party company. For example, the most recent smoke study, conducted on 12/30/2024, showed that the system meets the unidirectional airflow requirements as specified in the Unidirectional Airflow Test Protocol; however, no information, records, or videos demonstrating the smoke study was conducted under dynamic conditions were available for review.

Observation 5

Hazardous drugs and Highly potent drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.

Specifically,

A. The sterile compounding operators do not clean the ceiling area (with or without HEPA filter grids) inside the ISO 5 LAFHs or BSCs. For example, on 1/15/2025, after completing the compounding of TEST CYP/DHEA (SESAME) 200 mg/2.5mg/ml, Injectable Lot# 011 52025@ <Redacted B4> BUD 2/14/2025, the operator did not clean the ceiling area of the ISO 5 BSC (Equipment ID: 99302), a shared piece of equipment used for producing sterile hazardous drug products, biological products, and for radiolabeling blood cells. Additionally, the operator did not clean the interior 0 surfaces of the front shield of the ISO 5 LAFH during the end-of-day cleaning in Compounding Room <Redacted B4>

B. ...

Read the full 483 (Internet Archive copy FDA links)

Observation 6

Lack of disinfection of supplies at each transition from areas of lower quality air to areas of higher quality air.

Specifically,

A. The operator did not thoroughly disinfect supplies, such as needle packages, with <Redacted B4> before introducing them into the ISO 5 LAFH from the ISO 7 area. On 1/14/2025 and 1/15/2025, during the compounding of Semorelin Acetate Injection, 1 mg/ml, Lot# 01142025@ <Redacted B4> BUD 2/28/2025 and TEST CYP/DHEA (SESAME) 200 mg/2.5 mg/ml, Injectable Lot# 01152025@ <Redacted B4> BUD 2/14/2025, the operator sprayed multiple needle packages while holding them together in her hands with <Redacted B4>, leaving the contact surfaces between the needles insufficiently disinfected.

I

B. The paper-like bag containin&.(6) (4) cotton swabs, used to sample sterile products for microbiology testing, was not disinfected prior to being introduced into the ISO 5 LAFH or BSC given

• During the compounding of TRI-MIX 30/2/40 Injectable, Lot# 011 52025@ <Reacted B4> BUD 2/10/2025, the operator dropped an unopened bag of cotton swabs on the floor and immediately placed it inside the ISO 5 LAFH without disinfecting the bag's surfaces. ...

Read the full 483 (Internet Archive copy FDA links)

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for South Carolina are not checked: the Department of Labor, Licensing and Regulation’s board website did not respond to this index’s requests on November 6, 2026, or when tried again on November 7, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054020797LICENSED PHARMACYCAROLINA INFUSION LLCRIDGELAND, SCNOT RENEWED

GLP-1 warning letters

FDA’s posted warning letters that name a GLP-1 drug include 0 letters to Carolina Infusion, LLC. See the Carolina Infusion, LLC record page for those letters and any recalls.

No FDA warning letters in this index.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.